Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Open access
Fischer, Ute, Forster, Michael, Rinaldi, Anna, Risch, Thomas, Sungalee, Stéphanie, Warnatz, Hans-Jörg, Bornhauser, Beat, Gombert, Michael, Kratsch, Christina, Stütz, Adrian M, Sultan, Marc, Tchinda, Joelle, Worth, Catherine L, Amstislavskiy, Vyacheslav, Badarinarayan, Nandini, Baruchel, André, Bartram, Thies, Basso, Giuseppe, Canpolat, Cengiz, Cario, Gunnar, Cavé, Hélène, Dakaj, Dardane, Delorenzi, Mauro, Dobay, Maria Pamela, Eckert, Cornelia, Ellinghaus, Eva, Eugster, Sabrina, Frismantas, Viktoras, Ginzel, Sebastian, Haas, Oskar A, Heidenreich, Olaf, Hemmrich-Stanisak, Georg, Hezaveh, Kebria, Höll, Jessica I, Hornhardt, Sabine, Husemann, Peter, Kachroo, Priyadarshini, Kratz, Christian P, Kronnie, Geertruy te, Marovca, Blerim, Niggli, Felix, McHardy, Alice C, Moorman, Anthony V, Panzer-Grümayer, Renate, Petersen, Britt S, Raeder, Benjamin, Ralser, Meryem, Rosenstiel, Philip, Schäfer, Daniel, Schrappe, Martin, Schreiber, Stefan, Schütte, Moritz, Stade, Björn, Thiele, Ralf, Weid, Nicolas von der, Vora, Ajay, Zaliova, Marketa, Zhang, Langhui, Zichner, Thomas, Zimmermann, Martin, Lehrach, Hans, Borkhardt, Arndt, Bourquin, Jean-Pierre, Franke, Andre, Korbel, Jan O, Stanulla, Martin, Yaspo, Marie-Laure·2015·Nature Genetics

Abstract

TCF3-HLF−positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF−positive and treatment-responsive TCF3-PBX1−positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ng.3362

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 257

Metadata

Authors
Fischer, U., Forster, M., Rinaldi, A., Risch, T., Sungalee, S., Warnatz, H.-J., Bornhauser, B., Gombert, M., Kratsch, C., Stütz, A. M., Sultan, M., Tchinda, J., Worth, C. L., Amstislavskiy, V., Badarinarayan, N., Baruchel, A., Bartram, T., Basso, G., Canpolat, C., Cario, G., Cavé, H., Dakaj, D., Delorenzi, M., Dobay, M. P., Eckert, C., Ellinghaus, E., Eugster, S., Frismantas, V., Ginzel, S., Haas, O. A., Heidenreich, O., Hemmrich-Stanisak, G., Hezaveh, K., Höll, J. I., Hornhardt, S., Husemann, P., Kachroo, P., Kratz, C. P., Kronnie, G. T., Marovca, B., Niggli, F., McHardy, A. C., Moorman, A. V., Panzer-Grümayer, R., Petersen, B. S., Raeder, B., Ralser, M., Rosenstiel, P., Schäfer, D., Schrappe, M., Schreiber, S., Schütte, M., Stade, B., Thiele, R., Weid, N. V. D., Vora, A., Zaliova, M., Zhang, L., Zichner, T., Zimmermann, M., Lehrach, H., Borkhardt, A., Bourquin, J.-P., Franke, A., Korbel, J. O., Stanulla, M., & Yaspo, M.-L.
Venue
Nature Genetics
Published
2015-07-27
Volume
47
Issue
9
Pages
1020-1029
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2215798291
Cited by
257
References
78
FWCI
16.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.